Assessment of pharmacological safety of a new dipeptide mimetic of the 2nd loop of BDNF when co-administered with ethanol
https://doi.org/10.37489/2587-7836-2022-4-55-61
Abstract
To assess the pharmacological safety of the dipeptide mimetic of the 2nd loop of BDNF (compound GTS-201) when co-administered with ethanol, its effect on the alteration in motor activity induced by ethanol during acute and subchronic administration in mice C57Bl/6 and DBA/2 was studied. It was found that GTS-201 at a dose of 5.0 mg / kg, i.p., without affecting spontaneous motor activity per se, after a preliminary acute administration prevented the development of a sedative reaction caused by ethanol (2.0 g/ kg, i.p.) in C57Bl/6 mice. After subchronic administration, GTS-201 is devoid of psychostimulant effect and impact on the formation of ethanol-induced behavioral sensitization in DBA/2 mice. The data obtained indicate the absence of a psychostimulant component and synergism in the pharmacological profile of GTS-201 when used with ethanol at low dose.
About the Authors
A. V. Nadorova
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Nadorova Anna V., Research scientist, Laboratory of Pharmacological Regulation of Alcohol and Drug Addiction
Moscow
E. M. Grigorevskikh
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Grigorevskikh Ekaterina M., Research scientist, laboratory of pharmacological regulation of alcohol and drug addiction
Moscow
A. V. Tarasiuk
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Tarasiuk Aleksey V., Research scientist, Laboratory of Peptide Bioregulators of Medicinal Chemistry Department
Moscow
N. M. Sazonova
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Sazonova Nellya M., PhD, Cand. Chemistry Sci., senior research scientist, laboratory of peptide bioregulators of medicinal chemistry department
Moscow
L. G. Kolik
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Kolik Larisa G., Dr. Sci. (Biol.), professor RAS, Head laboratory of pharmacological regulation of alcohol and drug addiction
SPIN code: 9126-6922
Moscow
References
1. Al-Qerem W, Jarrar YB, Al-Sheikh I, El Maadani A. The prevalence of drug-drug interactions and polypharmacy among elderly patients in Jordan. Biomed Res. 2018;29(12):2561–2569. DOI: 10.4066/biomedicalresearch.29-18-618.
2. Hakkarainen KM, Hedna K, Petzold M, Hagg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions – a meta-analysis. PLoS One. 2012 Mar;7(3):e33236. DOI: 10.1371/journal.pone.0033236.
3. Pozniak V, Rekve D, editors. Global Strategy to Reduce Harmful Use of Alcohol. WHO; Geneve, Switzerland: 2010. [(accessed on 20 February 2020)]. pp. 1–44. WHO Reports.
4. Chan LN, Anderson GD. Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol). Clin Pharmacokinet. 2014 Dec;53(12):1115–1136. DOI: 10.1007/s40262-014-0190-x.
5. Aucamp AK, Weis OF, Müller FO, Gill CE, Malan J. Oxprenolol plus ethanol causes no central nervous system depression--a comparison with lorazepam plus ethanol. S Afr Med J. 1984 Sep 22;66(12):445–446.
6. Aranko K, Seppälä T, Pellinen J, Mattila MJ. Interaction of diazepam or lorazepam with alcohol. Psychomotor effects and bioassayed serum levels after single and repeated doses. Eur J Clin Pharmacol. 1985;28(5):559–565. DOI: 10.1007/BF00544067.
7. Abrahao KP, Quadros IM, Souza-Formigoni ML. Individual differences to repeated ethanol administration may predict locomotor response to other drugs, and vice versa. Behav Brain Res. 2009 Feb 11;197(2):404–410. DOI: 10.1016/j.bbr.2008.10.009.
8. Pietrzak B, Czarnecka E. Interaction between ethanol and diazepam in mice: chronobiological aspects. Pharmazie. 2005 Oct;60(10):761–764.
9. Ferraz IC, Boerngen-Lacerda R. Serotonin 5-HT2 receptor antagonist does not reverse established ethanolinduced sensitization but blocks its development and expression. Pharmacol Biochem Behav. 2008 Feb;88(4):456–464. DOI: 10.1016/j.pbb.2007.10.002.
10. Demarest K, Hitzemann B, Mahjubi E, McCaughran J Jr, Hitzemann R. Further evidence that the central nucleus of the amygdala is associated with the ethanolinduced locomotor response. Alcohol Clin Exp Res. 1998 Oct;22(7):1531–1537.
11. Hitzemann B, Hitzemann R. Chlordiazepoxide-induced expression of c-Fos in the central extended amygdala and other brain regions of the C57BL/6J and DBA/2J inbred mouse strains: relationships to mechanisms of ethanol action. Alcohol Clin Exp Res. 1999 Jul;23(7):1158–1172.
12. Botia B, Legastelois R, Houchi H, Naassila M. Basal anxiety negatively correlates with vulnerability to ethanol-induced behavioral sensitization in DBA/2J mice: modulation by diazepam. Alcohol Clin Exp Res. 2015 Jan;39(1):45–54. DOI: 10.1111/acer.12595.
13. Sazonova NM, Tarasyuk AV, Shumskii AN, Povarnina PYu, Kruglov SV, Antipova TA, Gudasheva TA, Seredenin SB. Synthesis and biological properties of a new dipeptide mimetic of brainderived neurotrophic factor loop 2. Pharmaceutical Chemistry Journal. 2018;52(9):763–770. (In Russ). DOI: 10.1007/s11094-018-1896-0.
14. Gudasheva TA, Logvinov IO, Nikolaev SV, Antipova TA, Povarnina PYu, Seredenin SB. Dipeptide mimetics of different NGF and BDNF loops activate PLC-γ1. Dokl Biochem Biophys. 2020;494(1):244–247. (In Russ). DOI: 10.1134/S1607672920050075.
15. Kolik LG, Nadorova AV, Grigorevskikh EM, Gudasheva TA, Seredenin SB. Experimental study of the anxiolytic activity of low-molecular-mass mimetics of the first, second and fourth loops of brain derived neurotrophic factor. Eksp Klin Farmakol. 2020;83(11):3–7 (In Russ). DOI:10.30906/0869-2092-2020-83-11-3-7.
16. Kolik LG, Nadorova AV, Grigorevskikh EM, Sazonova NM, Gudasheva TA, Durnev AD. Low-Molecular-Weight Mimetic of BDNF Loop 2 Reduces Ethanol Consumption in Female Rats. Bull Exp Biol Med. 2021 Aug;171(4):441–444. (In Russ). DOI: 10.1007/s10517-021-05245-w.
17. Kolik LG, Nadorova AV, Val'dman EA, Seredenin SB. Peculiarities of the effect of aminoadamantane derivatives on ethanolinduced ataxia, sedation, and hyperlocomotion in mice. Eksp Klin Farmakol. 2016;79(10):8–12. (In Russ). DOI: 10.30906/0869-2092-2016-79-10-8-12.
18. Kolik LG, Nadorova AV, Seredenin SB. Selank inhibits ethanol-induced hyperlocomotion and manifestation of behavioral sensitization in DBA/2 mice. Bull Exp Biol Med. 2016;162(1): 56–59. (In Russ). DOI: 10.1007/s10517-016-3544-6.
19. Kalluri HS, Ticku MK. Regulation of ERK phosphorylation by ethanol in fetal cortical neurons. Neurochem Res. 2003 May;28(5):765–769. DOI: 10.1023/a:1022822119560.
20. Chandler LJ, Sutton G. Acute ethanol inhibits extracellular signalregulated kinase, protein kinase B, and adenosine 3 ′:5 ′-cyclic monophosphate response element binding protein activity in an age- and brain region-specific manner. Alcohol Clin Exp Res. 2005 Apr;29(4):672–682. DOI: 10.1097/01.alc.0000158935.53360.5f.
21. Kalluri HS, Ticku MK. Ethanol-mediated inhibition of mitogenactivated protein kinase phosphorylation in mouse brain. Eur J Pharmacol. 2002 Mar 29;439(1-3):53–58. DOI: 10.1016/s0014-2999(01)01599-0.
22. Fattori V, Abe SI, Kobayashi K, Costa LG, Tsuji R. Effects of postnatal ethanol exposure on neurotrophic factors and signal transduction pathways in rat brain. J Appl Toxicol. 2008 Apr;28(3):370–376. DOI: 10.1002/jat.1288.
23. Li Z, Ding M, Thiele CJ, Luo J. Ethanol inhibits brain-derived neurotrophic factor-mediated intracellular signaling and activator protein-1 activation in cerebellar granule neurons. Neuroscience. 2004;126(1):149–162. DOI: 10.1016/j.neuroscience.2004.03.028.
24. Ohrtman JD, Stancik EK, Lovinger DM, Davis MI. Ethanol inhibits brain-derived neurotrophic factor stimulation of extracellular signal-regulated/mitogen-activated protein kinase in cerebellar granule cells. Alcohol. 2006 May;39(1):29–37. DOI: 10.1016/j.alcohol.2006.06.011.
Review
For citations:
Nadorova A.V., Grigorevskikh E.M., Tarasiuk A.V., Sazonova N.M., Kolik L.G. Assessment of pharmacological safety of a new dipeptide mimetic of the 2nd loop of BDNF when co-administered with ethanol. Pharmacokinetics and Pharmacodynamics. 2022;(4):55-61. (In Russ.) https://doi.org/10.37489/2587-7836-2022-4-55-61
Views:
477
Email this article 